CD34 and stroke disorder: Outcomes were assessed in a total of 475 patients for SAE (all-cause death) and 393 patients for SAE (recurrent stroke), 137 patients for CD34+ measurements, 389 patients for NIHSS, and 307 patients for Barthel Index.